Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 2 Nov 2026
Standard addition

STAG2 mutation predicts superior posttransplant survival in acute myeloid leukemia treated with low-intensity induction

STAG2 mutations predict better survival after transplant in AML, helping doctors identify which patients benefit most from this intensive treatment approach.

This retrospective cohort study found STAG2 mutation is associated with superior posttransplant survival in AML patients receiving low-intensity induction therapy. The finding adds STAG2 status as a clinically relevant prognostic biomarker for transplant outcomes, refining patient selection and post-transplant surveillance strategies.

What the study was

Study design
Retrospective cohort study
Population
AML/MDS patients receiving low-intensity induction and allogenic transplant
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
Blood cancer journal

Why it surfaced

Retrospective cohort study identifying STAG2 mutation as a prognostic biomarker for posttransplant survival in AML; directly applicable to transplant decision-making.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.